Family history of type 1 diabetes? What screening means after Tzield updates

If your family includes someone with type 1 diabetes, it may be worth asking about screening before symptoms start. CDC now says people with a family member who has type 1 diabetes should be offered screening, and that screening can begin at age 2.

That question feels more practical in 2026 than it did a few years ago. Current FDA labeling says Tzield (teplizumab) can be used in adults and children age 1 and older with stage 2 type 1 diabetes to delay progression to stage 3. Then, on June 12, 2026, FDA announced a separate approval for some children and teens ages 8 to 17 who were recently diagnosed with stage 3 type 1 diabetes. Screening still is not a crystal ball, and it is not the right next step for every family. But it can now lead to more specific conversations about monitoring, emergency planning, and whether treatment might be relevant.

Who should think about screening?

CDC says people with a family member who has type 1 diabetes are about 15 times more likely to develop it than the general population and should be offered screening. At the same time, CDC also notes an important limit: most people who develop type 1 diabetes do not have a family member with the condition. Family history matters, but it does not explain every case.

For most readers, the practical step is simple: if you are a parent, sibling, or close relative of someone with type 1 diabetes, ask a pediatrician, primary care clinician, or endocrinologist whether screening makes sense for your household.

What screening actually checks

This is not the same as routine blood sugar screening for type 2 diabetes. Early screening for type 1 diabetes usually starts with a blood test that looks for islet autoantibodies. These are signs that the immune system is attacking the insulin-making cells in the pancreas.

CDC explains the results this way:

No autoantibodies: a negative result. Right now, there is no settled guidance on exactly when or how often to repeat screening after a negative test.
One confirmed autoantibody: risk is higher, but this is not the same as having clinical diabetes.
Two or more confirmed autoantibodies: this means early-stage type 1 diabetes is present. Blood sugar testing is then used to determine the stage.

The stages matter because they describe where a person is in the disease process:

Stage 1: two or more autoantibodies, normal blood sugar, no symptoms.
Stage 2: two or more autoantibodies, abnormal blood sugar, no symptoms.
Stage 3: high blood sugar with symptoms present.

One detail can be confusing for families: CDC says screening can begin at age 2, while the current FDA stage 2 Tzield label now includes children as young as 1. That does not automatically mean every 1-year-old should be screened. It means screening and follow-up should be individualized with a qualified clinician.

What changed with Tzield in 2026

For stage 2 type 1 diabetes, the current FDA label says Tzield is used to delay the onset of stage 3 disease in adults and pediatric patients age 1 and older. The label requires confirmation of stage 2 disease, including at least two positive pancreatic islet autoantibodies and abnormal glucose testing without overt hyperglycemia. Treatment is given as a daily IV infusion for 14 days.

The newer June 12, 2026 FDA approval is a different use. It applies to children and teens ages 8 to 17 who were diagnosed with stage 3 type 1 diabetes within the past six weeks. In the FDA-reviewed trial, participants received one 12-day IV course and then another 12-day course six months later. FDA said the drug slowed the loss of the body’s own insulin production compared with placebo.

That does not mean Tzield cures type 1 diabetes. It also does not replace insulin in stage 3 disease. Children with symptomatic type 1 diabetes still need standard diabetes care, including insulin.

Why screening can matter even if treatment is never used

One of the biggest reasons screening matters is not just medication access. It is avoiding a dangerous first presentation. CDC says type 1 diabetes is often diagnosed as an emergency, sometimes only after diabetic ketoacidosis, or DKA, has already developed.

A 2026 systematic review and meta-analysis of youth screening programs found lower rates of DKA at diagnosis among screened groups. That does not mean every screening program will work the same way everywhere, but it supports a practical public-health point: families who know a child is at risk may be more likely to catch worsening blood sugar earlier and seek care before a crisis.

There are still real limits. Screening cannot tell a family exactly when stage 3 disease will begin. A negative result does not guarantee future protection. A positive result can also bring repeat testing, follow-up visits, and uncertainty that some families may find stressful.

Symptoms that should not wait for a screening appointment

Screening is for people who do not have symptoms. If a child or adult already has possible symptoms of stage 3 type 1 diabetes, the next step is medical evaluation, not waiting for a future screening conversation.

Warning signs can include:

frequent urination
excessive thirst
unexplained weight loss
unusual fatigue
blurred vision

Get urgent medical care right away if someone has symptoms that suggest DKA, such as vomiting, belly pain, deep or fast breathing, fruity-smelling breath, confusion, or rapidly worsening illness. Type 1 diabetes can progress quickly once symptoms start.

Safety and access issues families should know about

Tzield is not a casual treatment decision. The current FDA label carries a boxed warning for viral reactivation, including Epstein-Barr virus and cytomegalovirus. Other important risks include cytokine release syndrome, serious infections, low lymphocyte counts, and hypersensitivity reactions. Patients need testing and monitoring before and during treatment.

Access can vary too. CDC says free screening programs exist, including TrialNet for relatives of people with type 1 diabetes. The ASK program also offers free screening for children in the United States, including some without a family history. If a clinician orders testing through a local lab instead, coverage can vary by insurance plan. CDC says out-of-pocket screening costs are typically around $100 if insurance does not cover it. CDC also notes that Tzield can be very expensive without insurance coverage, though some patients may qualify for copay assistance.

Questions worth asking now

Does our family history make screening reasonable for this child or adult?
What test would be used, and what would a positive result change?
If antibodies are found, what stage are we talking about and who would manage follow-up?
If Tzield comes up, are we discussing stage 2 delay or recently diagnosed stage 3 treatment?
Would screening be covered through insurance, a hospital lab, or a free program?

The bottom line: for families with type 1 diabetes history, screening is no longer only about curiosity. It can affect follow-up, DKA prevention, and in some cases treatment options. But it still has limits, and it deserves a careful discussion with a qualified clinician, especially for very young children or anyone who may already have symptoms.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.